The largest database of trusted experimental protocols

Arima

Arima is a powerful analytical technique used in time series analysis and forecasting.
It stands for Autoregressive Integrated Moving Average, and is a class of statistical models that capture a wide range of depenedencies in data.
Arima models are particularly useful for analyzing and predicting trends, seasonality, and other patterns in time-dependent data, such as financial markets, weather, and economic indicators.
Reserachers can leverage Arima models to enhance the accuracy and reliability of their forecasts, enabling more informed decision-making across a variety of disciplines.

Most cited protocols related to «Arima»

Including a control series in ITS analysis improves causal inference, as ITS cannot exclude the possibility that any observed change was due to the intervention of interest, or another co-intervention or event. A control series is one that is not impacted by the intervention; selection of an appropriate control is described elsewhere [3 (link)]. As with ITS in segmented regression, including a control series involves running an ARIMA model for the series of interest, and separately for the control series [17 (link)]. If a change is observed in the intervention series but not the control series, this provides evidence that the impact was specific to the intervention.
Full text: Click here
Publication 2021
Arima
Chinese HFRS incidence data from 1975 to 2008 was obtained from the Chinese Center for Disease Control and Prevention. All HFRS cases were initially diagnosed by clinical symptoms. Patient blood samples were also collected and sent to local Centers for Disease Control and Prevention (CDC) laboratories for serological confirmation. Finally, data were collected by case number according to the sampling results. There might be admission rate bias in the disease report, but this has been reduced as much as possible. In China, HFRS is a nationally notifiable disease and hospital physicians must report every case of HFRS to the local health authority within 12 hours. Local health authorities later report monthly HFRS case totals to higher the national level CDC for surveillance purposes. Due to mandatory reporting, it is believed that the degree of compliance in disease notification over the study period was consistent.
We used the Box-Jenkins approach to ARIMA (p, d, q) modeling of time series [20 ]. This model-building process is designed to take advantage of associations in the sequentially lagged relationships that usually exist in periodically collected data [21 (link)]. The following were the parameters selected when fitting the ARIMA model: p, the order of autoregression; d, the degree of difference; q, the order of moving average.
The annual data used in this study did not show seasonal pattern, so the series was differenced at the non-seasonal level to induce stationarity. Autocorrelation function (ACF) graph and Partial autocorrelation function (PACF) graph were used to identify the order of moving average (MA) and autoregressive (AR) terms included in the ARIMA model. Estimates of the model's parameters were obtained by the conditional least squares method. Diagnostic checking including residual analysis and the Akaike Information Criterion (AIC) was used to compare the goodness-of-fit among ARIMA models. The Ljung-Box test was used to measure the ACF of the residuals. In addition, we used the mean absolute percentage error (MAPE) and fitting effect diagram to assess forecast accuracy.
, where xt and denote observed and fitted values at time point t. The MAPE value was calculated based on observed values and fitted values from 1978 to 2008. A lower MAPE value indicates a better fit of the data. Finally, the fitted ARIMA model was used for short-term forecasting of HFRS incidence for years 2009 to 2011. All analyses were performed using SAS9.1 with a significant level of p < 0.05.
Full text: Click here
Publication 2011
Arima BLOOD Chinese Diagnosis Disease Notification Hemorrhagic Fever with Renal Syndrome Patients Physicians
We used the mortality model previously published by Foreman and colleagues,22 (link) and extended it to 2100 with slight modifications. Briefly, the cause-specific model included three components: the underlying mortality, modelled as a function of the Socio-demographic Index (SDI), time, and additional cause-specific covariates where appropriate; a risk factor scalar that captured the combined risk factor effects for specific causes, based on the GBD 2017 cause-risk hierarchy and accounting for risk factor mediation;24 (link) and an autoregressive integrated moving average (ARIMA) model25 that accounted for unexplained residual mortality.
To accommodate long-range forecasts, we removed the spline on SDI and used a random walk with attenuated drift for the ARIMA model. Foreman and colleagues found that our mortality model had better out-of-sample predictive validity than the most widely used demographic forecasting model.22 (link) The method used to develop reference scenario values for each of the independent drivers in the mortality model was not modified from Foreman and colleagues.22 (link)
Full text: Click here
Publication 2020
Arima

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Arima Shock
We construct the seasonal ARIMA model written as ARIMA (p, d, q) (P, D, Q)s, where p, d and q stand for the autoregressive order, the number of nonseasonal differences and the moving average order, respectively, and P, D and Q stand for the seasonal autoregressive order, the number of seasonal differences and the seasonal moving average order, respectively. The s in the model represents the seasonal period length. In this study, we define the s as 12.9 (link) The construction of the ARIMA model in this study contains four steps. First, we apply both nonseasonal difference and seasonal difference methods to stabilize the series, since the incidence series plot shows a declining trend and seasonal fluctuations. The series is considered to be stationary after difference according to the Augmented Dickey-Fuller (ADF) test. Second, we identify parameters (p, q, P and Q) to establish plausible models by referring to the autocorrelation function (ACF) and partial autocorrelation function (PACF) plots based on the stationary series. We first determine the seasonal part parameters (P and Q) and then the nonseasonal part parameters (p and q) for the ARIMA model. The model with the lowest corrected Akaike’s information criterion (AICc) and Bayesian information criterion (BIC) is defined as the optimal model. Third, we use the maximum likelihood method to estimate the parameters and the Ljung-Box test to examine the residuals of the optimal model. The residuals should be white noise, indicating that the model completely extracted information from the original data. Moreover, the ACF and PACF plots of the residuals should show no significant correlation.26 (link)–28 (link) Finally, the optimal model is applied to predict the PTB incidence.
Publication 2019
Arima

Most recents protocols related to «Arima»

All data were stored on a secure drive accessible only to the study team. Statistical analyses were performed in Rstudio version 4.0.1 (Rstudio Team 2022 ). Using the NEISS-Work dataset, national ED-treated occupational injury count estimates were produced using the R packages “survey” and “srvyr” (Ellis et al. 2021 ; Lumley 2021 ) using the aforementioned NEISS-Work survey weights. ED-treated occupational injury count estimates were generated for all injuries and by injury event type, a categorical variable denoting the way an injury was incurred and is based on the aforementioned BLS OIICS v 2.01 classification system (National Institute for Occupational Safety and Health (NIOSH) Division of Safety Research 2021b ); all analyses were conducted both for total injury rate estimates and stratified by injury event type. ED-treated occupational injury rates were calculated per 10,000 FTE using Current Population Survey (CPS) estimates which were generated using NIOSH’s Employed Labor Force (ELF) query system; as NEISS-Work includes all work-related ED-treated injuries, FTE estimates were generated for all jobs (as opposed to “primary” or “secondary” jobs only) (National Institute for Occupational Safety and Health (NIOSH) Division of Safety Research 2021c ). Standard errors (SE) for FTE estimates were generated using generalized variance functions provided by BLS; standard errors were used to calculate monthly FTE variances by multiplying the square of the SE by corresponding ELF-generated monthly FTE estimates (i.e., the corresponding monthly sample size) (National Institute for Occupational Safety and Health (NIOSH) Division of Safety Research 2021c ). Variances of both numerator (injury count estimates) and denominator (FTE) data were used to calculate 95% confidence intervals (CI) for ED-treated occupational injury rate estimates based on Taylor series expansion (National Institute for Occupational Safety and Health (NIOSH) Division of Safety Research 2021d ) and were reported as injury rate estimates ± margin of error.
Seasonality of injury rate estimates was assessed by calculating seasonality indices per month. Seasonality indices were calculated by dividing the mean rate for each month by the mean monthly occupational injury rate for the entire dataset; seasonality indices of greater and less than one indicate higher than and lower than expected injury rates for a given month, respectively (Zhang et al. 2014 ).
To assess linear trends in injury rates over time, we fit a linear regression model to monthly injury rate estimates and adjusted for autocorrelation and serially correlated error terms using autoregressive integrated moving average (ARIMA) modeling. This analysis was conducted using both monthly total injury rate estimates and monthly estimates stratified by injury event type. In data violating the linear regression assumption of no autocorrelation, ARIMA models are used to control for serial correlation (e.g., seasonality) by including lagged dependent variable values and errors, including in studies of injury data (Box et al. 2016 ; Zhu et al. 2015 (link)). An ARIMA model takes the form ARIMA(p,d,q)(P,D,Q)m, where p is the order of autocorrelation, d is the number of differences applied to the data, q is the order of moving average terms, P, D, and Q are the seasonal versions of these terms, and m is the order of seasonality (e.g., 12 for annually seasonality in monthly data) (Hyndman and Athanasopoulos 2018a ). ARIMA models were fit to monthly injury rates by examining autocorrelation and partial autocorrelation plots. A lagged regression estimate was included if it showed statistical significance (p < 0.05) and was necessary to control for serial correlation. Finally, significance of each model’s Ljung-Box Q statistic was observed to ensure proper model fit, with a non-significant value considered a properly fit model (Ljung and Box 1978 ). The conditional sum of squares method was used to estimate all models. To assess temporal trends, a trend regressor with slope of one was included in each ARIMA model as a covariate and reported with 95% CIs (Hyndman and Athanasopoulos 2018b ). A total percent decrease in injury rates throughout the study period was estimated by multiplying this term by 96 (i.e., the total number of months in the study period) and calculating the percent difference from the model’s intercept; an analogous calculation using each trend parameter’s 95% CI was performed to determine each percent decrease’s 95% CI.
Full text: Click here
Publication 2023
Arima Injuries Labor Force Occupational Injuries Safety
We calculated incidence rates as number of cases (COVID-19 or admissions) divided by each country's population. We also calculated 7-day smoothed rolling average rates to reduce the effects of lower reporting on weekends.
We performed the first analysis on the 7-day smoothed data using NBSR. We also considered ARIMA models for autocorrelation.
To further strengthen the results and given that England did not implement the COVID-19 certification when it was effective in the other three countries, we used its data as a counterfactual for Difference-in-Differences (DiD) models. To help visualize this method, a plot of the difference and cumulative difference of the incidence rates for cases and hospitalizations of all countries is provided in Supplementary Figure 5. The numbers shown are essentially what constitute the basis of the DiD model. The differences have been calculated extracting England's incidence rates from the other countries' incidence rates. A decreasing trend in the difference's plots (on the left) is associated with a protective effect of the intervention date on the outcome.
We performed all the analyses in R v4.3 and used the packages epiR, tidyverse, forecast, ggplot2, MASS and lmtest. Code is available in https://github.com/KimLopezGuell/Covid-passport.
Full text: Click here
Publication 2023
Arima COVID 19 Hospitalization
We performed Negative binomial segmented regression (NB) and Autoregressive integrated moving average (ARIMA) models as a preliminary and sensitivity analysis of the main model, Difference-in-Differences. Detailed methods results and output for NB and ARIMA can be found in the Supplementary material.
Difference-in-Differences (DiD) methods compare the mean of the variable of interest for an exposed and control group, before and after a certain interruption point, providing insight on the changes of the variable for the exposed countries relative to the change in the negative outcome group (15 (link)). We cannot draw causal conclusions by simply observing before-and-after changes in outcomes, because other factors might influence the outcome over time. DiD methods overcome this by introducing a comparison between two similar groups exposed to different conditions. First, DiD takes the difference of the variable of interest of both groups before and after the intervention. Then it subtracts the difference of the control group to the difference of the exposed one to control for time varying factors, therefore giving a result which constitutes a difference of the differences. This approximates the clean impact of the intervention. In essence, the DiD estimating equation is the following,
where Ygt is the outcome for an individual in group g and treated unit t, Pt is a binary time variable indicating whether the observation belongs to the period before or after the intervention and Tg is a binary variable indicating whether the observation belongs to the exposed or the controlled group. In this setting, the treatment effect is estimated with the coefficient β3 from the regression.
For this method to be rightly used, all the typical OLS assumptions must be met. The parallel trends assumption, which requires both groups to present similar trends before the intervention time point (16 (link)), must also be satisfied. We tested all these assumptions, and the latter can be visually inspected in Figures 13.
DiD models produce estimates which consider a counterfactual group, therefore adjusting for unmeasured confounding. This cannot be done by neither of the two previous models. Its biggest limitation is that, in the end, the measured effect can only be attributed to the timepoint chosen. If that is due to the intervention placed then, or to other underlying reasons around the same time, cannot be known by design.
Full text: Click here
Publication 2023
Arima Hypersensitivity
HiC samples for mammalian cells were carried out using the Arima-HiC Kit (A510008, ARIMA Genomics) with some modifications. Briefly, the nuclei were prepared from 3 million cross-linked cells (−80°C) using Nuclei EZ prep (NUC101, Sigma-Aldrich) at 4°C for 10 min and spun down 500 × g at 1°C for 5 min. The nuclei wash was carried out in 0.09% bovine serum albumin (BSA)/CapC lysis buffer (10 mM Tris–Cl pH 8.0, 10 mM NaCl, 0.2% NP40, 0.09% BSA, and 1 tablet of EDTA-free protease inhibitor cocktail (11873580001, Roche) per 50 ml) at 4°C for 10 min and spun down at 500 × g at 1°C for 5 min. The nuclei pellets were resuspended in 25 μl of nuclease-free H2O (total volume of nuclei is ~30 μl). A 20-μl solution (~2 million) of freshly prepared nuclei was used for HiC sample preparation.
HiC libraries were generated using the Arima Library Prep module (A303011, ARIMA Genomics) as described by the manufacturers and sequenced using a NovaSeq6000 (Illumina). We used Illumina 150 bp paired end sequencing (300 cycle) to obtain ~1 billion read-pairs per sample.
The HiC dataset consists of the two biological replicated samples in OE19 cells. The paired-end reads of each sample were aligned to the human genome hg38 by the aligning software BWA-MEM v0.7.17 (Li and Durbin, 2010 (link)). The uniquely mapped reads were processed by the HiC data analysis pipeline Juicer v1.6 (Durand et al., 2016 (link)). The contacts identified in each of the two samples were stored in the.hic files. We applied the R package HiCRep with the default settings (Yang et al., 2017 (link)) to the contacts at MAPQ ≥ 30 to calculate the stratum-adjusted correlation coefficient (SCC) between the two replicates. As HiCRep calculated the SCC for the contacts on each chromosome, we calculated the chromosome-length weighted average of the SCCs on all the chromosomes as a summary SCC. The summary SCC for the two replicates is 0.965. We also applied the Juicer pipeline to the pool of the aligned reads from the two replicates and obtained the contacts from the merged reads of the two replicates.
The HiC data files of the two samples were uploaded in ArrayExpress repository with the ArrayExpress data ID E-MTAB-12664.
Full text: Click here
Publication 2023
Arima Biopharmaceuticals Buffers Cell Nucleus Cells Chromosomes DNA Library Edetic Acid Genome, Human Mammals Pellets, Drug SERPINA1 protein, human Serum Albumin, Bovine Sodium Chloride sodium copper chlorophyllin Tablet Tromethamine
We performed a retrospective chart review of all non-Jordanian cancer patients visiting KHCC between January 2018 to December 2021. The patients were defined as those being treated at KHCC due to cancer care inaccessibility in their home country due to conflict. Areas of conflict (e.g., wars, political unrest) included Iraq, Libya, Palestine, Sudan, and Syria. From KHCC’s Cancer Registry, which was established in 2006, the following was extracted for all potential patients: date at first contact, age at diagnosis, biological sex, cancer site, cancer histopathology, treatment type and duration, and SEER summary stage.
The data was analyzed using SPSS version 23. Categorical data were presented as frequencies [n (%)], while continuous data were reported as means ± standard deviations. Demographic and clinical data were described for the entire cohort and then stratified according to age group (adults vs. pediatrics, cut-off is 18 years of age), biological sex (male vs. female), year of first contact (i.e., 2018, 2019, 2020, 2021), and area of conflict (i.e., Iraq, Libya, Palestine, Sudan, Syria). For each stratum, the following was reported: frequency of cancer sites, SEER stage, treatment modalities, and mean age at diagnosis. Mean differences between certain subgroups in terms of continuous variables were examined using t-test and ANOVA.
The impact of COVID-19 on the number of admitted patients during the timeframe between 2018 and 2021 was modeled using Interrupted Time Series (ITS) analysis. The ITS model incorporated 3 distinct time frames which are a result of (1) the start of the national COVID-19 lockdown and (2) the end of all COVID-19 restrictions. Those time frames include: pre-COVID-19 era (January 2018 – February 2020), COVID-19 lockdown era (March 2020 – August 2021), and post-COVID-19 era (September 2021 – December 2021). Pre-COVID-19 data was collected as early as 2018 as to provide the model with a large enough number of observations for trend assessment. The Autoregressive Integrated Moving Average (ARIMA) model was used to evaluate the impact of COVID-19 lockdown on patients with cancer from areas of conflict. The SPSS Expert Modeler produced a best-fitting ARIMA model of (0,1,0). The fitness of the model and autocorrelations were assessed by the Ljung-Box Q test (p = 0.582). The model stationary R-squared and R-squared values were 0.759 and 0.754, respectively. All statistical tests were conducted with a 95% confidence interval and a 5% error margin. A p-value of less than 0.05 was considered statistically significant.
Full text: Click here
Publication 2023
Adult Age Groups Arima Biopharmaceuticals COVID 19 Diagnosis Males Malignant Neoplasms neuro-oncological ventral antigen 2, human Palestinians Patients Reading Frames Woman

Top products related to «Arima»

Sourced in United States, China, United Kingdom, Japan, Germany, Canada, Hong Kong, Australia, France, Italy, Switzerland, Sweden, India, Denmark, Singapore, Spain, Cameroon, Belgium, Netherlands, Czechia
The NovaSeq 6000 is a high-throughput sequencing system designed for large-scale genomic projects. It utilizes Illumina's sequencing by synthesis (SBS) technology to generate high-quality sequencing data. The NovaSeq 6000 can process multiple samples simultaneously and is capable of producing up to 6 Tb of data per run, making it suitable for a wide range of applications, including whole-genome sequencing, exome sequencing, and RNA sequencing.
Sourced in United States
The Accel-NGS 2S Plus DNA Library Kit is a laboratory equipment product designed for the preparation of DNA libraries for next-generation sequencing (NGS) applications. The kit provides a streamlined workflow for the construction of high-quality sequencing libraries from a variety of input DNA samples.
Sourced in United States, China, Germany, United Kingdom, Canada, Switzerland, Sweden, Japan, Australia, France, India, Hong Kong, Spain, Cameroon, Austria, Denmark, Italy, Singapore, Brazil, Finland, Norway, Netherlands, Belgium, Israel
The HiSeq 2500 is a high-throughput DNA sequencing system designed for a wide range of applications, including whole-genome sequencing, targeted sequencing, and transcriptome analysis. The system utilizes Illumina's proprietary sequencing-by-synthesis technology to generate high-quality sequencing data with speed and accuracy.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, China, United Kingdom, Sweden, Germany, Australia, Cameroon
The NovaSeq platform is a high-throughput sequencing system designed for genomic research. It features a modular architecture and offers multiple flow cell configurations to accommodate a wide range of sample sizes and sequencing applications. The NovaSeq platform is capable of generating large volumes of high-quality sequencing data, making it suitable for various genomic studies and applications.
Sourced in United States, China, United Kingdom, Hong Kong, France, Canada, Germany, Switzerland, India, Norway, Japan, Sweden, Cameroon, Italy
The HiSeq 4000 is a high-throughput sequencing system designed for generating large volumes of DNA sequence data. It utilizes Illumina's proven sequencing-by-synthesis technology to produce accurate and reliable results. The HiSeq 4000 has the capability to generate up to 1.5 terabytes of data per run, making it suitable for a wide range of applications, including whole-genome sequencing, targeted sequencing, and transcriptome analysis.
Sourced in United States, Switzerland, China, Germany, Japan
The KAPA Hyper Prep Kit is a DNA library preparation kit designed for high-throughput sequencing. It enables efficient and rapid construction of sequencing libraries from various DNA input sources.
Sourced in United States, China, United Kingdom, Germany, Italy, Sweden, Japan, Switzerland
The NovaSeq 6000 system is a high-throughput next-generation sequencing (NGS) platform designed for large-scale genomic research. It is capable of generating high-quality sequencing data across a wide range of applications, including whole-genome sequencing, exome sequencing, and targeted gene panels.
Sourced in United States, China, United Kingdom, Germany, France, Sweden, Singapore, Canada, Switzerland, Japan
The NovaSeq is a high-throughput DNA sequencing system developed by Illumina. It is designed to perform large-scale, whole-genome sequencing and other genomic applications. The NovaSeq utilizes Illumina's proprietary sequencing-by-synthesis technology to generate high-quality sequencing data.

More about "Arima"

ARIMA (Autoregressive Integrated Moving Average) is a powerful statistical technique used in time series analysis and forecasting.
It is a class of models that can capture a wide range of dependencies in data, making it particularly useful for analyzing and predicting trends, seasonality, and other patterns in time-dependent data, such as financial markets, weather, and economic indicators.
ARIMA models are versatile and can be adapted to fit various types of time series data.
They consist of three main components: autoregressive (AR), integrated (I), and moving average (MA).
The AR component models the relationship between the current value and past values in the series, the I component handles non-stationarity by differencing the data, and the MA component models the relationship between the current value and past errors.
Researchers and analysts can leverage ARIMA models to enhance the accuracy and reliability of their forecasts, enabling more informed decision-making across a variety of disciplines.
This can be particularly useful in fields like finance, where accurate predictions of stock prices, market trends, and economic indicators are crucial.
In addition to ARIMA, other powerful analytical techniques like SAS 9.4, NovaSeq 6000, and KAPA Hyper Prep Kit can also be employed to enhance research workflows and data analysis.
The NovaSeq 6000 system, for example, is a high-throughput sequencing platform that can generate vast amounts of genetic data, which can then be analyzed using ARIMA and other statistical models.
By combining the insights gained from ARIMA and other advanced analytical tools, researchers can improve the accuracy and reproducibility of their work, leading to more robust and impactful findings.
The PubCompare.ai platform can help researchers identify the best protocols and products for their research needs, streamlining their workflow and elevating their research.